Soleil Boughton Sells 2,345 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,345 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25. Following the completion of the transaction, the insider now owns 159,796 shares of the company’s stock, valued at $2,341,011.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, August 6th, Soleil Boughton sold 2,334 shares of Hims & Hers Health stock. The stock was sold at an average price of $17.30, for a total value of $40,378.20.
• On Tuesday, July 23rd, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.29, for a total value of $47,377.15.
• On Tuesday, July 9th, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.28, for a total transaction of $47,353.80.

Hims & Hers Health Stock Down 5.4 %

Shares of NYSE:HIMS opened at $13.65 on Friday. Hims & Hers Health, Inc. has a 12-month low of $5.65 and a 12-month high of $25.74. The firm has a market capitalization of $2.93 billion, a P/E ratio of -1,365.00 and a beta of 1.05. The firm has a fifty day moving average of $18.36 and a two-hundred day moving average of $16.76.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The firm had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. During the same quarter last year, the firm earned ($0.03) earnings per share. The business’s revenue for the quarter was up 51.8% on a year-over-year basis. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Bank of America increased their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. Finally, Citigroup downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and an average price target of $20.29.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its stake in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC increased its stake in shares of Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the period. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health during the 2nd quarter worth about $111,000. Belpointe Asset Management LLC boosted its stake in Hims & Hers Health by 10.0% during the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after purchasing an additional 1,205 shares during the period. Finally, Amalgamated Bank grew its holdings in Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.